FDA gives go-ahead to AstraZeneca vaccine
The Food and Drug Administration (FDA) approved AstraZeneca’s viral vector vaccine after studying the 10,000 pages of documentation submitted on December 22, FDA chief Paisan Dankhum said on Thursday.
The approval is based on effectiveness, quality and safety. The import licence and vaccine certificate is effective for one year.
The first lot of 50,000 doses will be imported from Italy next month. When the vaccine arrives, the Department of Medical Sciences will conduct random tests to see if the vaccine is of the quality specified by the company. Similar batches will be sent in March and April.
As for the manufacturing deal signed between AstraZeneca and Siam Bioscience, a factory will be registered and production will kick off in May.
